Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg

DRUG2 trials

Sponsors

Boryung Pharmaceutical Co., Ltd

Conditions

Diabete MellitusDiabetes Mellitus

Phase 1

A Study to Evaluate the Pharmacokinetics and Safety Between BR3006 and Co-administration of BR3006A, BR3006B, and BR3006C in Healthy Adult Volunteers (Fasting)

RecruitingNCT07083388

Boryung Pharmaceutical Co., LtdDiabetes Mellitus

Start: 2025-07-03End: 2026-07-03Target: 52Updated: 2025-07-24

A Study to Evaluate the Pharmacokinetics and Safety Between BR3006 and Co-administration of BR3006A, BR3006B, and BR3006C in Healthy Adult Volunteers (Fed)

RecruitingNCT07083401

Boryung Pharmaceutical Co., LtdDiabete Mellitus

Start: 2025-07-05End: 2026-07-05Target: 40Updated: 2025-07-24